Royalty Pharma plc Financing Receivable, Change in Present Value, Expense (Reversal)
Royalty Pharma plc (RPRX) reported Financing Receivable, Change in Present Value, Expense (Reversal) of -$21.72 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinancingReceivableChangeInPresentValueExpenseReversal · last filed 2022-02-15
- Royalty Pharma plc financing receivable, change in present value, expense (reversal) for the quarter ending 2021-12-31 was $0.00.
- Royalty Pharma plc financing receivable, change in present value, expense (reversal) for the quarter ending 2021-09-30 was -$2.00K.
- Royalty Pharma plc financing receivable, change in present value, expense (reversal) for the quarter ending 2020-12-31 was -$5.93M.
- Royalty Pharma plc financing receivable, change in present value, expense (reversal) for the quarter ending 2020-09-30 was $0.00.
- Royalty Pharma plc financing receivable, change in present value, expense (reversal) for fiscal 2021 was -$21.72M.
- Royalty Pharma plc financing receivable, change in present value, expense (reversal) for fiscal 2020 was -$2.96M.
- Royalty Pharma plc financing receivable, change in present value, expense (reversal) for fiscal 2019 was -$95.16M.
- Royalty Pharma plc financing receivable, change in present value, expense (reversal) for fiscal 2018 was -$5.64M.
| Period end | Financing Receivable, Change in Present Value, Expense (Reversal) 3 month | Financing Receivable, Change in Present Value, Expense (Reversal) 6 month | Financing Receivable, Change in Present Value, Expense (Reversal) 9 month | Financing Receivable, Change in Present Value, Expense (Reversal) 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$2.00K derived: sum of 2 quarters · filed 2022-02-15 | -$21.72M 10-K · filed 2022-02-15 | |
| 2021-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$21.72M 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | -$21.72M 10-Q · filed 2021-08-11 | |||
| 2020-12-31 | -$5.93M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$5.93M derived: sum of 2 quarters · filed 2022-02-15 | -$2.96M 10-K · filed 2022-02-15 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $2.96M 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | $2.96M 10-Q · filed 2020-08-12 | |||
| 2019-12-31 | -$95.16M 10-K · filed 2022-02-15 | |||
| 2018-12-31 | -$5.64M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |